We innovate and advance novel therapies to provide greater choice and freedom to broad patient populations.
Brii Biosciences is a biotechnology company developing therapies to address some of the world’s most common public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice.
Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline.
Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.
To tackle public health challenges through breakthrough scientific innovation and critical patient insights
We believe there has never been a better time to dramatically change the way healthcare is developed and delivered.
Patients and their families are at the forefront of every decision we make. People around the world are suffering from a variety of diseases that require bespoke treatment modalities and there is no “one size fits all” solution. We are not only working to innovate novel treatment options with disease modifying potential, but to develop and advance those treatments in ways that enable patients greater freedom from their health conditions.
Building trust with patients, society, healthcare providers, regulators, public health advocates, corporate partners, and our employees is central to our core business strategy. We are committed to continuing our work with healthcare providers and governments to address some of the biggest public health concerns around the world.
Our primary goal is to deliver positive impact for patients, public health and society. We invest in medicines that have the potential to make a profound difference in many peoples’ lives. We will not leave patients behind, and we will continue our work to ensure patient safety and benefit always come ahead of profit.
It is critical that patients and their physicians have confidence that Brii Bio’s medicines are produced and administered with the highest quality standards. We invest heavily to ensure quality control and assurance of our products, including across manufacturing and supply, with enhanced oversight for the proper use of our medicines.